Undifferentiated Carcinoma — Trials

Undifferentiated Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

162 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 46
Recruiting: 15
Ph III recruiting: 3
Growth YoY: —
Industry share: 4%
Top sponsor: National Cancer Institute (NCI)
Termination share: 29.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (30)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06362694	Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy	unknown	Phase 2	10	Saint Petersburg State University, RussiaOTHER	1	Apr 12, 2024	clinicaltrials
NCT05102292	The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation	unknown	Phase 1 / Phase 2	25	Shanghai Henlius BiotechINDUSTRY	1	Aug 21, 2023